Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial

The Lancet

Volumn 387, Issue 10021, 2016, Pages 857-865

  Ganz, Patricia A ^a,b   Cecchini, Reena S ^c,d   Julian, Thomas B ^a,e   Margolese, Richard G ^a,f   Costantino, Joseph P ^c,d   Vallow, Laura A ^a,g   Albain, Kathy S ^a,h,i   Whitworth, Patrick W ^a,j,k   Cianfrocca, Mary E ^a,h,l,m   Brufsky, Adam M ^a,n   Gross, Howard M ^a,o   Soori, Gamini S ^a,p   Hopkins, Judith O ^a,q,r   Fehrenbacher, Louis ^a,s   Sturtz, Keren ^a,t   Wozniak, Timothy F ^a,u   Seay, Thomas E ^a,v   Mamounas, Eleftherios P ^a,w   Wolmark, Norman ^a,e  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NRG Oncology   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g MAYO CLINIC   (United States)

^h Southwest Oncology Group   (United States)

ⁱ LOYOLA UNIVERSITY CHICAGO   (United States)

^j Cancer Programs   (United States)

^k Nashville Breast Center   (United States)

^l AMERICAN COLLEGE OF RADIOLOGY   (United States)

^m Banner MD Anderson Cancer Center   (United States)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

^o Hematology and Oncology   (United States)

^p MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^q National Cancer Institute   (United States)

^r Forsyth Regional Cancer Center   (United States)

^s KAISER PERMANENTE   (United States)

^t Christiana Care Health Systems ^*  (United States)

^u CHRISTIANA CARE HEALTH SYSTEM   (United States)

^v Atlanta Regional Community Clinical Oncology Program Research Group   (United States)

^w UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; HORMONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BLADDER DISEASE; BODY WEIGHT DISORDER; CANCER RADIOTHERAPY; CANCER SURGERY; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GYNECOLOGIC DISEASE; HEALTH STATUS; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MENTAL HEALTH; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL PAIN; NORTH AMERICA; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; SHORT FORM 12; TREATMENT OUTCOME; VAGINA DISEASE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NITRILES; POSTMENOPAUSE; QUALITY OF LIFE; TAMOXIFEN; TRIAZOLES;

EID: 84959535858     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01169-1     Document Type: Article

References (26)

1. American Cancer Society Breast Cancer Facts and Figures 2015-2016 2015 American Cancer Society Atlanta
2. B Fisher, J Costantino, C Redmond et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer N Engl J Med 328 1993 1581 1586
3. B Fisher, J Dignam, N Wolmark et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17 J Clin Oncol 16 1998 441 452
4. B Fisher, S Land, E Mamounas, J Dignam, ER Fisher, N Wolmark Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience Semin Oncol 28 2001 400 418
5. B Fisher, J Dignam, N Wolmark et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1999 1993 2000
6. SA Narod, J Iqbal, V Giannakeas, V Sopik, P Sun Breast cancer mortality after a diagnosis of ductal carcinoma in situ JAMA Oncol 1 2015 888 896
7. PA Ganz Quality-of-life issues in patients with ductal carcinoma in situ J Natl Cancer Inst Monogr 2010 2010 218 222
8. JM Gierisch, ER Myers, KM Schmit et al. Prioritization of research addressing management strategies for ductal carcinoma in situ Ann Internal Med 160 2014 484 491
9. M Baum, AU Budzar, J Cuzick et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
10. L Fallowfield, D Cella, J Cuzick, S Francis, G Locker, A Howell Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial J Clin Oncol 22 2004 4261 4271
11. D Cella, L Fallowfield, P Barker, J Cuzick, G Locker, A Howell Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) Trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 2006 273 284
12. RG Margolese, RS Cecchini, TB Julian et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial Lancet 2015 published online Dec 10. http://dx.doi.org/10.1016/S0140-6736(15)01168-X
13. B Fisher, JP Costantino, DL Wickerham et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
14. R Day, PA Ganz, JP Costantino, WM Cronin, DL Wickerham, B Fisher Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Clin Oncol 17 1999 2659 2669
15. VG Vogel, JP Costantino, DL Wickerham et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
16. SR Land, DL Wickerham, JP Costantino et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2742 2751
17. PA Ganz, R Day, JE Ware Jr, C Redmond, B Fisher Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial J Natl Cancer Inst 87 1995 1372 1382
18. J Ware Jr, M Kosinski, SD Keller A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity Med Care 34 1996 220 233
19. SF-36 Health Survey Manual and Interpretation Guide 1993 The Health Institute, New England Medical Center Boston, MA
20. AL Stanton, CA Bernaards, PA Ganz The BCPT Symptom Scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer J Natl Cancer Inst 97 2005 448 456
21. D Cella, SR Land, CH Chang et al. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women Breast Cancer Res Treat 109 2008 515 526
22. EM Andresen, JA Malmgren, WB Carter, DL Patrick Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale) Am J Prev Med 10 1994 77 84
23. LS Radloff The CES-D Scale: a self-report depression scale for research in the general population Appl Psychol Meas 1 1977 385 401
24. CD Sherbourne Social functioning: sexual problems measures AL Stewart JE Ware Measuring Functioning and Well-Being: The Medical Outcomes Study Approach 1992 Duke University Press Durham, NC 195 204
25. J Bonneterre, B Thürlimann, JFR Robertson et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study J Clin Oncol 18 2000 3748 3757
26. JM Nabholtz, A Buzdar, M Pollak et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758 3767